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The host inflammatory response is a
crucial determinant of disease outcome
and correlates with disease severity
in SARS-CoV-2-induced infection, for
which there is no treatment to date.
Activation of transcription factor nuclear
factor erythroid 2 p45-related factor
2 (NRF2) promotes resolution of inflam-
mation and, in parallel, restores cellular
redox and protein homeostasis, and
facilitates tissue repair.
NRF2 can be activated by pharmaco-
logical inducers that target Kelch-like
ECH-associated protein 1 (KEAP1),
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Acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 is largely
the result of a dysregulated host response, followed by damage to alveolar
cells and lung fibrosis. Exacerbated proinflammatory cytokines release (cytokine
storm) and loss of T lymphocytes (leukopenia) characterize the most aggressive
presentation. We propose that a multifaceted anti-inflammatory strategy based
on pharmacological activation of nuclear factor erythroid 2 p45-related factor
2 (NRF2) can be deployed against the virus. The strategy provides robust
cytoprotection by restoring redox and protein homeostasis, promoting resolu-
tion of inflammation, and facilitating repair. NRF2 activators such as sulforaph-
ane and bardoxolone methyl are already in clinical trials. The safety and
efficacy information of these modulators in humans, together with their well-
documented cytoprotective and anti-inflammatory effects in preclinical models,
highlight the potential of this armamentarium for deployment to the battlefield
against COVID-19.NRF2.
The available information on pharma-
cokinetics, pharmacodynamics, safety,
and efficacy for the NRF2 activators
sulforaphane and bardoxolone methyl
(currently in advanced clinical trials for
other disease indications) in humans
makes them excellent candidates for
testing in randomized clinical trials in
COVID-19.
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UKExacerbated Inflammation in Severe COVID-19 Pathology
Numerous clinical observations during the outbreaks of coronaviruses – severe acute respiratory syn-
drome coronavirus (SARS-CoV), Middle East respiratory syndrome-related coronavirus (MERS-CoV),
and most recently SARS-CoV-2 – convincingly show that, in addition to virus propagation, the host
inflammatory response is a crucial determinant of disease outcome [1]. A parallel can be drawn
with influenza, for which lethality is not associated with the cytolytic action of the pathogen but instead
with the inflammatory response orchestrated by the host immune system [2]. In the most severe
cases of the disease, a cytokine storm (excess production of cytokines) [3] is associated with T cell
depletion, pulmonary inflammation, and lung damage. Patients showing acute respiratory distress
syndrome (ARDS; see Glossary) and other types of virus-induced pneumonia also present features
ofmacrophage activation syndrome (MAS) [3]. There is also evidence of leukopenia, with a ~two-
fold decrease in T cell number [4], which may be the result of pyroptosis, a form of cell death that
mainly affects cells of the immune system [5]. On the other hand, granulocytosismight be partly re-
sponsible for the strong burst of superoxide [2], a type of reactive oxygen species (ROS) [6], and
the additional production of proinflammatory cytokines [7].
To comprehensively manage the symptoms of COVID-19 (the disease caused by SARS-CoV-2),
it is crucial to understand the most appropriate context for introducing an anti-inflammatory
therapy to complement an antiviral therapy. Such therapy must control inflammation without
altering the ability of the host to mount an efficient adaptive immune response against the virus.
We propose that boosting endogenous cellular defenses by targeting the cytoprotective tran-
scription factor NRF2 (gene name NFE2L2) will promote the resolution of COVID-19 associated598 Trends in Pharmacological Sciences, September 2020, Vol. 41, No. 9 https://doi.org/10.1016/j.tips.2020.07.003
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Trends in Pharmacological Sciencesinflammation and also restore redox homeostasis and facilitate tissue repair. It should be noted
that the protein under discussion is distinctly separate from the identically abbreviated nuclear
respiratory factor 2 (also known as GA binding protein transcription factor subunit β, gene name
GABPB1), a completely different transcription factor involved in mitochondrial biogenesis [8].
Overview of NRF2 and Its Anti-Inflammatory Roles
NRF2 is a cap'n'collar (CNC) transcription factor that heterodimerizes with small musculoaponeu-
rotic fibrosarcoma (sMAF) proteins, K, G, or F [9], or with transcription factors C-JUN and JUND
[10], to bind to antioxidant response elements (AREs), and regulates the transcription of target
genes, including those encoding proteins involved in cellular redox homeostasis, detoxification,
macromolecular damage repair, and metabolic balance [11]. Under basal conditions, NRF2
interacts with the E3 ligase substrate adapter Kelch-like ECH-associated protein 1 (KEAP1)
that targets the transcription factor for ubiquitination and proteasomal degradation [11–13]
(Figure 1, Key Figure). Electrophiles and ROS (collectively termed inducers) inactivate KEAP1
by modifying specific sensor cysteine residues [14], resulting in NRF2 accumulation and
enhanced target gene transcription.
NRF2 activity is frequently dysregulated in disease states, including diabetes, liver disease, and
inflammatory bowel disease [15], and declines with aging [16]. Some of these disease states
(e.g., diabetes) and older age are risk factors associated with SARS-CoV-2-induced ARDS
[17]. Importantly, activation of NRF2 has been shown to be involved in preserving lung architec-
ture in response to inflammatory cues, and therapeutic effects of NRF2 activation have been
reported in animal models of several lung disorders, including respiratory infections and ARDS
[18]. Moreover, single-nucleotide polymorphisms (SNPs) located in the promoter region of
NFE2L2 (encoding NRF2) have been implicated in lung disease susceptibility in humans, hence
reinforcing NRF2 as therapeutic target for pulmonary diseases [19,20].
NRF2 also plays a role in both the execution and the resolution of inflammation [12] by repressing
proinflammatory genes such as IL6 and IL1B [21]. This is particularly prominent in lipopolysaccha-
ride (LPS)-stimulated macrophage cells, where the anti-inflammatory immunometabolite
itaconate, that accumulates during metabolic reprogramming of these cells, activates NRF2
[22]. Moreover, NRF2 also induces the transcription of several macrophage-specific genes that
participate in tissue repair. These include macrophage receptor with collagenous structure
(MARCO), a receptor required for bacterial phagocytosis, cluster of differentiation 36 (CD36), a
scavenger receptor for oxidized low-density lipoproteins (LDL) [24], and IL-17D [25], which confer
protection against viral infections [26]. Similarly, NRF2 activation restores redox homeostasis by
upregulating glutathione (GSH), NADPH, thioredoxin, thioredoxin reductase, and peroxiredoxin
that protect against oxidative stress and favor alternative wound healing versus classical
proinflammatory activation of macrophages and other immune cells [27].
NRF2 in Viral Infections
The role of NRF2 in viral infections has been investigated in the context of both DNA and RNA
viruses. In general, viruses can benefit from either activating or inhibiting NRF2 in host cells
[28]. This might be dependent on factors such as the stage of infection [29] or the specific mech-
anisms of viral propagation – that favor either death of the infected cells and lytic release of virions,
or survival of the infected cells with reduction of the inflammatory response to help viral propaga-
tion [30]. For human coronavirus HCoV-229E, which is associated with the common cold and
pulmonary disease [31], deficiency in expression of the NRF2 target gene glucose-6-phosphate
dehydrogenase (G6PDH) increases ROS production and enhances viral gene expression and
particle production [32]. Crucially, the NRF2 pathway has been found to be suppressed in lungTrends in Pharmacological Sciences, September 2020, Vol. 41, No. 9 599
Glossary
Acute respiratory distress
syndrome (ARDS): a type of
respiratory failure characterized by rapid
onset of widespread inflammation in the
lungs which impairs their ability to
exchange oxygen and carbon dioxide.
Angiotensin-converting enzyme 2
(ACE2): a transmembrane receptor
protein that is found in lungs, arteries,
heart, kidney, and intestine, and which
serves as the main entry point into cells
for SARS- CoV and SARS-CoV2.
Antioxidant response elements
(AREs): specific DNA sequences in the
promoter regions of NRF2-dependent
genes.
Bioavailability: the proportion of a drug
or other substance which, when
introduced into the body, enters the
circulation and is thus able exert
biological effects.
Electrophile: a chemical species that is
attracted to an electron-rich center.
Electrophiles are chemically reactive
and, by accepting an electron pair, binds
to nucleophiles.
Glutathione (GSH): the most
abundant thiol in animal cells; N90% of
total glutathione is in the reduced form
(GSH), and the remainder is in the
disulfide form (GSSG). An increased
GSSG/GSH ratio is indicative of
oxidative stress.
Granulocytosis: an increase in
number of granulocytes (basophils,
eosinophils, and neutrophils) in the
peripheral blood.
Macrophage activation syndrome
(MAS): a potentially fatal complication of
rheumatic diseases; MAS is
characterized by high fever and can be
associatedwith hemorrhage, damage to
the liver, kidney, and the central nervous
system, and may lead to multiple organ
failure.
NAD(P)H:quinone oxidoreductase 1
(NQO1): a homodimeric FAD-binding
protein that catalyzes the obligatory two-
electron reduction of quinones to
hydroquinones, thus preventing redox
cycling and glutathione depletion. NQO1
is a classical NRF2-regulated gene and
is used as a marker of NRF2
transcriptional activity.
Nonsteroidal anti-inflammatory
drugs (NSAIDs): inhibitors of the
activity of cyclooxygenases (COX-1 or
COX-2) that catalyze the biosynthesis of
prostaglandins (involved in inflammation)
and thromboxanes (involved in blood
clotting).
Trends in Pharmacological Sciencesbiopsies from COVID-19 patients; conversely, pharmacological inducers of NRF2 inhibit the
replication of SARS-CoV2 and the inflammatory response [33].
Interestingly, there is reciprocal crosstalk between NRF2 and NF-κB in inflamed tissues, where
innate immune cells are recruited [34–36]. Following infection with SARS-CoV, NF-κB is activated
in lungs of mice and in human monocyte macrophages in vitro; conversely, inhibition of NF-κB
decreases inflammation and improves survival after SARS-CoV infection in mice [7,37]. Thus,
pharmacological activation of NRF2 might also limit NF-κB-mediated inflammatory processes
inflicted in the lung by SARS-CoV-2 infection.
SARS-CoV-2 Biology and Potential Crosstalk with NRF2
The SARS-CoV-2 genome encodes non-structural proteins (nsp) that are required for replication,
structural proteins including spike (S), envelope (E), membrane (M), and nucleocapsid (N), and
accessory proteins ORF3, 6, 7a, 7b, 8, and 9b that interact with the host cells [38]. The
receptor-binding domain (RBD) located in the S protein of SARS-CoV-2 interacts with
the angiotensin-converting enzyme 2 (ACE2) of host cells to allow viral entry (Figure 1) [39].
The use of ACE inhibitors/angiotensin-receptor blockers, which are widely prescribed to patients
with cardiovascular pathologies [40], is currently being considered for COVID-19 (clinical trial
numbersi NCT04311177 and NCT04312009 for the use of losartan) because angiotensin II,
the target of ACE inhibitors, has vasoconstrictive, proinflammatory, pro-oxidative, and
prothrombotic effects [41]. However, these inhibitors alter the balance ACE/ACE2 and increase
ACE2 levels, thus potentially increasing the number of docking sites for viral entry [42]. NRF2
deficiency is known to upregulate ACE2, whereas its activator oltipraz reduces ACE2 levels
[43], suggesting that NRF2 activation might reduce the availability of ACE2 for SARS-CoV-2
entry into the cell (Figure 1).
By analogy with other coronaviruses, SARS-CoV-2 is expected to modulate the host translational
machinery to favor the generation of its own proteins (Figure 1) [44]. Host countermeasures to this
step include inactivation of eukaryotic initiation factor 2 (eIF2) by two of the three cellular eIF2α
kinases, protein kinase R (PKR) and PKR-like endoplasmic reticulum kinase (PERK), which are
known to be activated in response to SARS-CoV infection [45]. Interestingly, PKR also has the
potential to upregulate the autophagy cargo protein p62, which competes with NRF2 for binding
to KEAP1 [46] and further promotes the autophagic degradation of KEAP1 [47], thus activating
NRF2 transcriptional activity (Figure 1). Moreover, it has been observed in SARS-CoV infection
that host-induced blockade of translation of coronavirus proteins, including the S protein, triggers
the unfolded protein response (UPR), activating PERK [48] that phosphorylates and activates
NRF2 [49]. This may thus be one step at which NRF2 can bemodulated to reduce the potential of
SARS-CoV-2 infection of host cells.
Cells infected with RNA viruses recognize viral molecular patterns, especially nucleic acids, by
cytoplasmic and endosomal receptors, such as the RNA sensors retinoic acid-inducible gene I
(RIG-I) and melanoma differentiation-associated protein 5 (MDA-5) [50], and the DNA sensor
cyclic GMP-AMP synthase (cGAS), which signals through the adaptor protein stimulator of
interferon genes (STING) to mediate an appropriate immune response [51]. These innate
detection systems activate interferon regulatory factor 3 (IRF3)-mediated transcription of type I
and III interferons (IFNs) [51]. Coronavirus infections (including SARS-CoV) have been shown to
antagonize STING-mediated host immune systems [52,53]. Although type I IFNs are crucial for
restricting viral replication and spread by activating autocrine and paracrine type I IFN receptor
signaling, excessive release of IFNs by infected pulmonary alveolar cells or resident macrophages
may exacerbate the pulmonary infiltration of additional monocyte-derived macrophages, further600 Trends in Pharmacological Sciences, September 2020, Vol. 41, No. 9
Oxidative stress: imbalance between
oxidants and antioxidants in favor of the
oxidants, leading to disruption of cellular
redox signaling and damage to proteins,
lipids, and DNA.
Reactive oxygen species (ROS):
unstable oxygen-containing molecules
formed by redox reactions or by
electronic excitation.
Stimulator of interferon genes
(STING): an adaptor protein associated
with the endoplasmic reticulum, which is
essential for transcription of host
defense genes, including type I
interferons (IFNs) and proinflammatory
cytokines, following recognition of
aberrant DNA species or cyclic
dinucleotides (CDNs) in the cytosol.
Unfolded protein response (UPR): a
homeostatic signaling network that is
activated following endoplasmic
reticulum stress and results in functional
recovery of the organelle.
Trends in Pharmacological Sciencespotentiating inflammatory damage [54]. NRF2 downregulates IFN production, in part by down-
regulating STING expression [55,56] (Figure 1). Therefore, NRF2 may attenuate the inflammatory
response to viral infection by preventing excessive production of IFNs.
In addition, upregulation of the NRF2-transcriptional target heme oxygenase 1 (HO-1, gene
name HMOX1) has been linked to an antiviral response against many viruses including HIV,
hepatitis C virus (HCV), hepatitis B virus (HBV), enterovirus 71 (E71), influenza virus, respiratory
syncytial virus (RSV), Dengue virus (DENV), and Ebola virus (EBOV) [57]. HO-1 can mediate
antiviral responses by forming a heterodimeric complex with IRF3 [58]. With this interaction,
IRF3 is phosphorylated and translocated into the nucleus where it induces the expression of
type I IFNs (Figure 2).
Several other mechanisms have been described for the control of viral infection by HO-1, which
can be extrapolated to some extent to SARS-CoV-2. HO-1 catalyzes the degradation of heme
into three products, biliverdin, Fe2+, and CO, each with putative anti-SARS-CoV-2 activity.
Coronaviruses produce viral proteases – 3C-like proteinase (3CL-pro) and papain-like protease
(PLpro) – that process the viral polyproteins and are essential for viral replication [59]. Both
3CL-Pro and PLpro share high homology with other viral proteases [60] that are known to be
inhibited by biliverdin [61] (Figure 2). Biliverdin is then expected to inhibit both SARS-CoV-2
3CLpro and PLpro. Free Fe2+ binds to the highly conserved divalent metal-binding pocket of
RdRp of HCV, inhibiting its enzymatic activity (Figure 2) [62,63]. Because this binding pocket is
highly conserved in SARS-CoV-2 [64] a similar mechanism may confer NRF2/HO-1-mediated
antiviral activity against COVID-19. Furthermore, CO elicits antiviral responses against positive-
sense single-stranded RNA (+ssRNA) viruses such as E71 [65] and bovine viral diarrhea virus
(BVDV9) [66], and this effect is phenocopied by the CO donor, CO-releasing molecule 2
(CORM-2), through a mechanism that depends on the activation of soluble guanylyl cyclase
(sGC), which increases the local levels of cGMP and activates protein kinase G (PKG)
(Figure 2). In turn, PKG inhibits NADPH oxidase (NOX) [67], preventing an increase in ROS levels
(Figure 2) that otherwise would contribute to inflammation. If these mechanisms are also mirrored
in the context of COVID-19, activation of the NRF2/HO-1 pathway holds promise for mitigating
SARS-CoV-2 infection.
Armamentarium of Available NRF2 Activators for Potential Anti-Inflammatory
Therapy of COVID-19
An important limitation for the development of effective therapies against SARS-Cov-2 is the
poor reproducibility of COVID-19 in animal models, most of which do not share relevant
physiology, do not mount an appropriate immune response, or do not present relevant
clinical symptoms [68]. Nevertheless, genetic or pharmacological NRF2 activation has con-
sistently demonstrated anti-inflammatory and antiviral effects in other pathologies in animals
and in humans. The most physiologically and pharmacologically relevant mechanism of
NRF2 regulation is by targeting specific cysteine sensors within KEAP1 [11]. A comprehen-
sive review on the use of NRF2 activators against viral infections has been published recently
[69]. Given that changes in redox homeostasis in infected cells and lung inflammation
are hallmarks of infections caused by respiratory viruses [70], the information obtained
from viruses that affect the airways may be relevant for extrapolation to COVID-19. Indeed,
experimental evidence is beginning to emerge, and it was recently demonstrated that the
NRF2 activators dimethyl fumarate (DMF) and 4-octyl itaconate (4-OI), a cell-permeable
analog of the endogenous anti-inflammatory metabolite itaconate [22], suppress the inflammatory
response to SARS-CoV2 in human cells, including peripheral blood mononuclear cells (PBMCs)
from COVID-19 patients [33].Trends in Pharmacological Sciences, September 2020, Vol. 41, No. 9 601
Key Figure
Putative Viral Cycle of SARS-CoV2 Highlighting Points of Potential Crosstalk with NRF2 Activation
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Figure 1. Steps 1–7 depict the different steps of the viral cycle. (1) Binding of the viral spike (S) protein to ACE2 leads to virion entry. NRF2 has been shown to repressACE2
gene expression in rats [43]. (2) The viral nucleocapsid is uncoated in the cytoplasm of the host cell. (3) Translation of the viral positive-sense single-stranded RNA (+ssRNA)
and cleavage of the translation product into specific viral proteins. Viral RNA inside the host cell activates the DNA/RNA sensor cGAS, which signals through the adaptor
STING [117], and induces the expression of type I and III interferons (IFNs). NRF2 represses IFN production by downregulating STING expression [56]. (4) Replication of the
viral genome. NRF2 induces the expression of HO-1, generating Fe2+ that can bind to the divalent metal-binding pocket of the RNA-dependent RNA polymerase (RdRp)
of SARS-CoV2 and inhibit its catalytic activity [63,64]. (5) Translation of structural proteins. Host defense is conducted by double-stranded RNA-activated protein kinase
R (PKR), which phosphorylates eIF2 and inhibits protein translation. PKR also phosphorylates p62, thus activating NRF2 upon removal of its repressor KEAP1 by
autophagy [118]. Inhibition of protein translation in turn activates the unfolded protein response (UPR). PERK, a crucial Ser/Thr protein kinase in UPR signaling,
phosphorylates NRF2, resulting in its stabilization and increased transcriptional activity [49]. (6) Virion assembly. (7) Release of viral particles. Abbreviations: ACE2,
angiotensin-converting enzyme 2; eIF2, eukaryotic initiation factor 2; ER, endoplasmic reticulum; ERGIC, ER–Golgi intermediate compartment; HO-1, heme oxygenase
1; IFN, interferon; KEAP1, Kelch-like ECH-associated protein 1; NRF2, nuclear factor erythroid 2 p45-related factor 2; PERK, PKR-like endoplasmic reticulum kinase;
P, phosphorylation; PKR, protein kinase R; STING, stimulator of interferon genes. Figure generated with Biorender (https://biorender.com/).
Trends in Pharmacological SciencesThe NRF2 activators targeting KEAP1 that are under clinical development have been recently
described [11,71]. We discuss below DMF, the only drug approved by the US Food and Drug
Administration (FDA) and the European Medicines Agency (EMA) that targets the NRF2/KEAP1
axis [72], as well as two types of NRF2 activators that have been tested in advanced clinical trials602 Trends in Pharmacological Sciences, September 2020, Vol. 41, No. 9
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Figure 2. Antiviral Activity of HO-1, a Target of NRF2. HO-1 catalyzes the degradation of heme into carbon monoxide
(CO), Fe2+, and biliverdin. Free Fe2+ is expected to bind to the highly conserved divalent metal-binding pocket of the viral
RNA-dependent RNA polymerase (RdRp). Carbon monoxide activates soluble guanylyl cyclase (sGC) to generate cGMP,
thus activating protein kinase G (PKG), which inhibits NAPDH oxidases (NOX), preventing an increase in reactive oxygen
species (ROS). By inhibiting the SARS-CoV-2 proteases 3CLpro and PLpro, biliverdin is expected to suppress the
proteolytic maturation of viral polypeptides. Heterodimerization of HO-1 with IRF3 facilitates the phosphorylation and
nuclear translocation of IRF3 and the induction of type I IFN gene expression. Abbreviations, HO-1, heme oxygenase 1;
IFN, interferon; ISRE, interferon-sensitive response element; IRF3, interferon regulatory factor 3; NRF2, nuclear factor
erythroid 2 p45-related factor 2; P, phosphorylation. Figure generated with Biorender (https://biorender.com/).
Trends in Pharmacological Sciences(Table 1), and thus can be immediately expedited to clinical trials to examine their therapeutic
efficacy in patients with COVID-19.
Dimethyl Fumarate
DMF is used in the treatment of multiple sclerosis (MS) and psoriasis, and may have beneficial
effect in lung diseases [73]. Consistent with its role in preventing demyelination, DMF protects
against Theiler's murine encephalomyelitis virus (TMEV), a +ssRNA virus that causes a MS-like
disease, via enhancing the NRF2 antioxidant and anti-inflammatory responses as well as
suppressing IL-17A [74]. However, a well-characterized off-target effect, not related to the
NRF2/KEAP1 axis, is leukopenia that occurs in a subset of MS patients [75]. Considering that
leukopenia is a hallmark of severe cases of COVID-19, the potential use of DMF in this setting
should be considered with caution.
Sulforaphane
The isothiocyanate sulforaphane (SFN), originally isolated from broccoli, a cruciferous vegetable,
as an inducer of the classical NRF2 target, NAD(P)H:quinone oxidoreductase 1 (NQO1) [76],
is themost potent naturally occurring NRF2 activator, with well-documented antioxidant and anti-
inflammatory effects [77]. The high bioavailability of SFN and its stabilized α-cyclodextrin-Trends in Pharmacological Sciences, September 2020, Vol. 41, No. 9 603
Table 1. Selected Clinical Trials of Relevance to Inflammation and Infection of Sulforaphane and Its Encap-
sulated Variant Sulfodarex (SFX-01), and Bardoxolone-Methyl and Its Structural Analog Omaveloxolone
(RTA-408), Four NRF2 Activators That Target KEAP1
Compounda Disease Clinical trial Clinical trial
identifieri
Sulforaphane Healthy Phase I NCT01008826
Phase I NCT02023931
Chronic obstructive pulmonary disease (COPD) Phase II NCT01335971
Asthma Phase I NCT01845493
Phase I NCT01845493
Phase I/II NCT01183923
Aging Phase II NCT03126539
Allergic rhinitis Phase II NCT02885025
Helicobacter pylori infection Phase IV NCT03220542
Type 2 diabetes mellitus Phase II NCT02801448




Pulmonary hypertension Phase III NCT03068130
Phase III NCT02657356
Renal insufficiency
Type 2 diabetes mellitus
Phase II NCT01053936




Chronic kidney disease associated with type 1
diabetes mellitus
Focal segmental glomerulosclerosis
Autosomal dominant polycystic kidney disease
Phase II NCT03366337
Chronic renal insufficiency
Type 2 diabetes mellitus
Phase III NCT01351675




Alport syndrome Phase II/III NCT03019185
Omaveloxolone (RTA-408)
R = NHCOCF2CH3
Inflammation and pain following ocular surgery Phase II NCT02065375





Radiation dermatitis in breast cancer Phase II NCT02142959
aThe pink circles on the chemical structures indicate the electrophilic carbon that undergoes nucleophilic attack by cysteine
151 of KEAP1.
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Trends in Pharmacological Sciencesencapsulated version sulforadex (SFX-01) makes it an excellent candidate for alleviating exces-
sive anti-inflammatory responses and protecting the lungs. SFN has been found to be protective
in animal models of respiratory disease, including an ARDSmodel in rabbits [78] and a hyperoxia-
induced pulmonary injury model in mice [79]. It also limits RSV replication and virus-induced
inflammation in the lungs of wild-type, but not NRF2-null, mice [80]. In HIV-1 transgenic rats,
SFN increased GSH levels and the expression of NQO1, and restored the tight junctions between
the alveolar epithelial cells [81]. In an in vitromodel of influenza A infection, SFN reduced both viral
cell entry and replication [82]. In addition, SFN suppresses HCV replication [83] and reduces
HSV-1 virion production [29]. Interestingly, SFN inhibits nucleotide-binding oligomerization domain
(NOD)-, leucine-rich repeat (LRR)-, and pyrin domain-containing protein (NLRP) 1 and 3
inflammasomes (crucial innate immune components that shape host immune homeostasis) as
well as pyroptosis, partly in anNRF2-independentmanner [84].Moreover, an interesting study con-
ducted in smokers (a patient cohort with higher risk of lung infections, damage etc.) showed that
SFN increased the expression of NQO1 in cells of nasal lavage fluid and, upon infection with live at-
tenuated influenza virus, lowered the levels of IL-6 and viral load [85].
Sources of sulforaphane, including standardized broccoli extracts, dietary supplements, and
encapsulated stabilized sulforaphane (Prostaphane and SFX-01) have been in numerous clinical
trials for indications that range from lung disease to inflammatory diseases which are closely
related to COVID-19 pathophysiology. These include chronic obstructive pulmonary disease
(COPD), asthma, allergy, rhinitis, aging, diabetes mellitus, Helicobacter pylori infection, and
subarachnoid hemorrhage (Table 1). The clinical trials provide extensive pharmacokinetics,
pharmacodynamics, safety, and efficacy information [77] that can be extrapolated to COVID-19.
Notably, most of these trials have recommended cruciferous-free diets during the study period
to minimize baseline noise and accurately detect the plasma and urinary levels of sulforaphane
and its metabolites [86].
Bardoxolone Methyl (CDDO-Me) and Omaveloxolone (RTA-408)
Semisynthetic pentacyclic triterpenoids derived from the natural product oleanolic acid rep-
resent the most potent NRF2 activators known to date, with activities in the sub- to low-
nanomolar concentration range [87]. An early study highlighted that the anti-inflammatory
and NRF2-inducer potencies of 18 triterpenoids correlated linearly over six orders of magni-
tude of concentration, suggesting that the two processes are mechanistically linked [88].
Some triterpenoids isolated from Ganoderma lucidum have been found to be potential inhib-
itors of the NS2B-NS3 protease of DENV [89]. A study conducted in 2003 after the SARS
outbreak [90] found that glycyrrhizin, a triterpenoid from liquorice roots, inhibited the replica-
tion of SARS-CoV in two clinical isolates of coronaviruses from patients with SARS. The
potential effect of glycyrrhizin on NRF2 was not studied; however, glycyrrhizin has been
shown to activate NRF2 in other settings [77,91], and it is plausible that at least part of
the observed antiviral effect was due to NRF2 activation.
Bardoxolone methyl (CDDO-Me), a semisynthetic pentacyclic triterpenoid, has been shown
to possess a broad-spectrum anti-inflammatory activity against both DENV and Zika virus
(ZIKV) [92]. In preclinical models, bardoxolone methyl alleviated LPS-induced acute lung
injury through NRF2-dependent suppression of inflammation and oxidative stress [93]. The
antiviral properties of bardoxolone methyl have also been shown in cell culture models of
HBV, HCV, and HSV1 infections, where it reduced intracellular HBV RNA pre-genome
levels, suppressed HCV genome replication [94], and inhibited the production of HSV1
virions [29]. Bardoxolone methyl and a closely related analog, omaveloxolone (RTA-408),
are currently in clinical trials for various indications where inflammation and oxidative stressTrends in Pharmacological Sciences, September 2020, Vol. 41, No. 9 605
Outstanding Questions
How does SARS-CoV-2 downregulate
NRF2 in the host cells, and does this
depend on the stage of the viral
infection?
Does NRF2 contribute to metabolic
reprogramming and adaptation of
macrophages and T cells, and does it
affect their anti-inflammatory functions
during the course of COVID-19?
Can pharmacological activation of
NRF2 decrease SARS-CoV-2 entry
into host cells?
Do all NRF2 activators reduce replication
and virion production, or do they affect
other stages of propagation of SARS-
CoV-2?
If they do, does this effect depend on
NRF2 and/or HO-1?
Trends in Pharmacological Sciencesunderlie disease pathogenesis, including pulmonary hypertension, pulmonary arterial hyper-
tension, and ocular inflammation (Table 1) [95].
It is important to note that, even though NRF2 is the primary mediator, additional factors contrib-
ute to the anti-inflammatory effects of SFN, bardoxolone methyl, and omaveloxolone (RTA-408).
Thus, SFN inhibits NF-κB [96], inhibitor of NF-κB kinase subunit β (IKKβ), and STAT3 [98],
whereas bardoxolone methyl inhibits IKKβ [99] and STAT3 and STAT5 activation [100]. Overall,
the combined NRF2-activating and anti-inflammatory effects of these compounds culminate in
highly robust cytoprotection. These compounds potentially warrant exploration for the manage-
ment of COVID-19 symptoms.
NRF2 Activators versus Other Anti-Inflammatory Approaches to COVID-19
The exacerbated inflammation observed in COVID-19 patients could potentially be treated with
anti-inflammatory drugs such as corticosteroids and nonsteroidal anti-inflammatory drugs
(NSAIDs). Indeed, the RECOVERY (randomised evaluation of COVID-19 therapy) trial, a random-
ized multicenter clinical trial in COVID-19 patients from National Health Service (NHS) hospitals in
the UK, found that low-dose dexamethasone, a corticosteroid, reduced mortality in ventilated
patients and in patients receiving oxygen only, although it had no effect in patients not receiving
respiratory support [101].
Although results with NSAIDs are not conclusive in people with COVID-19 [102], ibuprofen, an
NSAID, has been shown to impair neutrophil function, their recruitment to the inflammatory
site, and the resolution of inflammatory processes in patients with pneumonia [103]. However,
ibuprofen is associated with higher rates of nephrotoxicity [104], cardiovascular disease, and
stroke [105], and appears to increase the risk for these outcomes in ARDS [106]. A significant
difference between NSAIDs and NRF2 activators is that NRF2 elicits a muchmore integrated reg-
ulation of the inflammatory response because it is necessary for both execution and resolution.
Furthermore, by regulating the endogenous cytoprotective systems, NRF2 may have a
more physiological role in achieving a balance between the beneficial and adverse effects of
inflammation.
Another alternative to conventional anti-inflammatory drugs that holds great promise in COVID-19
is the use of drugs that target cytokines involved in the cytokine storm in COVID-19. This includes
targeting IL-6 and IL-1 signaling [107]. Tocilizumab (a humanized monoclonal antibody against
the IL-6 receptor) and anakinra (a recombinant human IL-1 receptor antagonist) are being
repurposed and studied in COVID-19 [108,109]. Use of NRF2 activators represents an excellent
alternative or parallel to these approaches because it is known that NRF2 inhibits IL-6 and IL-1β
gene expression [21].
Concluding Remarks and Future Perspectives
In the past few months, COVID-19, a disease caused by a novel coronavirus SARS-CoV-2, has
had a tremendous health and socioeconomic impact at a global scale. We propose here a poten-
tial anti-inflammatory therapy based on pharmacological targeting of transcription factor NRF2.
We envisage that the benefits of pharmacological activation of NRF2 in the context of SARS-
Cov-2 infection will be threefold: (i) increasing fitness and providing protection to the host cell;
(ii) promoting the anti-inflammatory phenotype during macrophage activation, thus preventing
uncontrolled production of proinflammatory cytokines and pyroptosis; and (iii) inhibiting viral
propagation. Notably, unlike direct antioxidants such as vitamin C, that are short-lived
(minutes to hours) and are consumed in the process of ROS scavenging, the antioxidant
and cytoprotective effects of NRF2 activation are long-lasting and persist for several days after606 Trends in Pharmacological Sciences, September 2020, Vol. 41, No. 9
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small molecules, have long half-lives [11] and are not consumed, and are instead regenerated
during the reactions which they catalyze [112].
Most NRF2 inducers, including DMF, sulforaphane, and bardoxolone methyl, are electrophiles
that modify cysteine sensors of KEAP1 and inactivate its repressor function. Concerns in using
electrophilic NRF2 activators include: (i) possible toxicity at high doses – electrophiles react
with GSH and thus, at high doses, may cause GSH depletion; indeed an electrophilic metab-
olite is responsible for the hepatotoxicity of high doses of acetaminophen [113]. (ii) Possible
perturbations of redox signaling owing to persistent NRF2 activity. Both concerns can be re-
solved by careful selection of dose and dosing regimen in the design of clinical trials, such as
including periods of NRF2 activation only during times of active disease with the aim of restor-
ing redox balance and resolving inflammation. Moreover, experimental evidence suggests that
the maximally tolerated dose of sulforaphane (and other electrophiles) is not necessarily the
most effective [114]. This realization is driving research that aims to identify non-electrophilic
NRF2 activators, which inhibit binding to KEAP1, and where promising candidates are
emerging [71,115,116].
An area of potential interest for developing COVID-19 candidate drugs in the NRF2 pathway
would be to identify inhibitors of the transcriptional repressor BTB domain and CNC homolog 1
(BACH1) that shows increased levels as NRF2 activation declines with age (a risk factor in
COVID-19) [18].
Collectively, the research discussed strongly suggests that NRF2 activation holds promise as
a strategy against COVID-19. However, before implementing this strategy it is desirable to
address several important issues (see Outstanding Questions). For example, the finding that
SARS-CoV-2 inhibits NRF2 [33] indicates that the virus deprives the host cells of an essential
cytoprotective pathway, and it will be crucial to determine how and when during the process of
the viral infection this takes place, and the underlying mechanism. It is presently unclear whether
NRF2 can contribute to metabolic reprogramming and adaptation of macrophages and T cells,
and whether it affects their effector functions during the course of COVID-19. It will also be impor-
tant to establish whether pharmacological activation of NRF2 can suppress the entry of SARS-
CoV-2 into the host cell, how NRF2 activators reduce the replication of SARS-CoV-2, and whether
this effect depends on NRF2, HO-1, or the broader network of proteins regulated by NRF2.
Nonetheless, the wealth of safety and efficacy information for NRF2 activators such as
sulforaphane and bardoxolone methyl, that are already in advanced clinical trials for other indica-
tions, provides a clear route for their testing in randomized clinical trials in patients with COVID-
19. If successful, this therapeutic strategy could be rapidly mobilized to improve recovery and
decrease the need for mechanical ventilation in patients with severe COVID-19, relieving the
enormous strain that is currently being experienced by intensive care units worldwide.
Acknowledgments
We are grateful to the Biotechnology and Biological Sciences Research Council (BB/L01923X/1), Tenovus Scotland
(T17/14), Cancer Research UK (C20953/A18644), the Autonomous Community of Madrid (grant B2017/BMD-3827), the
'Tatiana de Guzman el Bueno Foundation' (P-024-FTPGB 2018), and the European Regional Development Fund, Compet-
itiveness Operational Program 2014–2020 (P_37_732/2016; REDBRAIN) for funding our research.
Disclaimer Statement
A.T.D-K. is a member of the Scientific Advisory Board of Evgen Pharma and is a consultant for Aclipse Therapeutics and
Vividion Therapeutics. A.C. is a consultant for Aclipse Therapeutics.Trends in Pharmacological Sciences, September 2020, Vol. 41, No. 9 607
Trends in Pharmacological SciencesResource
ihttps://www.clinicaltrials.gov/
References
1. Guan, W.J. et al. (2020) Clinical characteristics of coronavirus
disease 2019 in China. N. Engl. J. Med. 382, 1861–1862
2. Galani, I.E. and Andreakos, E. (2015) Neutrophils in viral
infections: current concepts and caveats. J. Leukoc. Biol. 98,
557–564
3. Huang, C. et al. (2020) Clinical features of patients infected
with 2019 novel coronavirus in Wuhan, China. Lancet 395,
497–506
4. Qin, C. et al. (2020) Dysregulation of immune response in
patients with COVID-19 in Wuhan, China. Clin. Infect. Dis.
Published online March 12, 2020. https://doi.org/10.1093/
cid/ciaa248
5. Fung, S.Y. et al. (2020) A tug-of-war between severe acute
respiratory syndrome coronavirus 2 and host antiviral defence:
lessons from other pathogenic viruses. Emerg. Microbes
Infect. 9, 558–570
6. Sies, H. and Jones, D.P. (2020) Reactive oxygen species
(ROS) as pleiotropic physiological signalling agents. Nat. Rev.
Mol. Cell Biol. 21, 363–383
7. DeDiego, M.L. et al. (2014) Inhibition of NF-kappaB-mediated
inflammation in severe acute respiratory syndrome coronavirus-
infected mice increases survival. J. Virol. 88, 913–924
8. Jornayvaz, F.R. and Shulman, G.I. (2010) Regulation of mito-
chondrial biogenesis. Essays Biochem. 47, 69–84
9. Otsuki, A. and Yamamoto, M. (2020) Cis-element architecture
of Nrf2–sMaf heterodimer binding sites and its relation to
diseases. Arch. Pharm. Res. 43, 275–285
10. Venugopal, R. and Jaiswal, A.K. (1998) Nrf2 and Nrf1 in associa-
tion with Jun proteins regulate antioxidant response element-
mediated expression and coordinated induction of genes
encoding detoxifying enzymes. Oncogene 17, 3145–3156
11. Cuadrado, A. et al. (2019) Therapeutic targeting of the NRF2
and KEAP1 partnership in chronic diseases. Nat. Rev. Drug
Discov. 18, 295–317
12. Cuadrado, A. et al. (2018) Transcription factor NRF2 as a
therapeutic target for chronic diseases: a systems medicine
approach. Pharmacol. Rev. 70, 348–383
13. Hayes, J.D. and Dinkova-Kostova, A.T. (2014) The Nrf2 regula-
tory network provides an interface between redox and interme-
diary metabolism. Trends Biochem. Sci. 39, 199–218
14. Dinkova-Kostova, A.T. et al. (2002) Direct evidence that sulfhy-
dryl groups of Keap1 are the sensors regulating induction of
phase 2 enzymes that protect against carcinogens and
oxidants. Proc. Natl. Acad. Sci. U. S. A. 99, 11908–11913
15. Rabbani, P.S. et al. (2019) Dysregulation of Nrf2/Keap1 redox
pathway in diabetes affects multipotency of stromal cells.
Diabetes 68, 141–155
16. Schmidlin, C.J. et al. (2019) Redox regulation by NRF2 in aging
and disease. Free Radic. Biol. Med. 134, 702–707
17. Wu, C. et al. (2020) Risk factors associated with acute respira-
tory distress syndrome and death in patients with coronavirus
disease 2019 pneumonia in Wuhan, China. JAMA Intern.
Med. 180, 1–11
18. Liu, Q. et al. (2019) Role of Nrf2 and its activators in respiratory
diseases. Oxidative Med. Cell. Longev. 2019, 7090534
19. Acosta-Herrera, M. et al. (2015) Common variants of NFE2L2
gene predisposes to acute respiratory distress syndrome in
patients with severe sepsis. Crit. Care 19, 256
20. Hua, C.C. et al. (2010) Functional haplotypes in the promoter
region of transcription factor Nrf2 in chronic obstructive pulmo-
nary disease. Dis. Markers 28, 185–193
21. Kobayashi, E.H. et al. (2016) Nrf2 suppresses macrophage
inflammatory response by blocking proinflammatory cytokine
transcription. Nat. Commun. 7, 11624
22. Mills, E.L. et al. (2018) Itaconate is an anti-inflammatory metabolite
that activates Nrf2 via alkylation of KEAP1. Nature 556, 113–117
24. Harvey, C.J. et al. (2011) Targeting Nrf2 signaling improves bacte-
rial clearance by alveolar macrophages in patients with COPD and
in a mouse model. Sci. Transl. Med. 3, 78ra32
25. Seelige, R. et al. (2017) The ancient cytokine IL-17D is regulated
by Nrf2 and mediates tumor and virus surveillance. Cytokine 91,
10–12
26. Saddawi-Konefka, R. et al. (2016) Nrf2 induces IL-17D to mediate
tumor and virus surveillance. Cell Rep. 16, 2348–2358
27. Brune, B. et al. (2013) Redox control of inflammation in
macrophages. Antioxid. Redox Signal. 19, 595–637
28. Deramaudt, T.B. et al. (2013) Regulation of oxidative stress by
Nrf2 in the pathophysiology of infectious diseases. Med. Mal. In-
fect. 43, 100–107
29. Wyler, E. et al. (2019) Single-cell RNA-sequencing of herpes sim-
plex virus 1-infected cells connects NRF2 activation to an antiviral
program. Nat. Commun. 10, 4878
30. Halder, U.C. et al. (2011) Cell death regulation during influenza A
virus infection by matrix (M1) protein: a model of viral control over
the cellular survival pathway. Cell Death Dis. 2, e197
31. Gorse, G.J. et al. (2009) Human coronavirus and acute respiratory
illness in older adults with chronic obstructive pulmonary disease.
J. Infect. Dis. 199, 847–857
32. Wu, Y.H. et al. (2008) Glucose-6-phosphate dehydrogenase de-
ficiency enhances human coronavirus 229E infection. J. Infect.
Dis. 197, 812–816
33. Olagnier, D.P. et al. (2020) Identification of SARS-CoV2-mediated
suppression of NRF2 signaling reveals a potent antiviral and anti-
inflammatory activity of 4-octyl-itaconate and dimethyl fumarate.
Nat. Commun. Published online May 27, 2020. http://dx.doi.
org/10.21203/rs.3.rs-31855/v1
34. Cuadrado, A. et al. (2014) Transcription factors NRF2 and
NF-kappaB are coordinated effectors of the Rho family, GTP-
binding protein RAC1 during inflammation. J. Biol. Chem. 289,
15244–15258
35. Lastres-Becker, I. et al. (2014) Fractalkine activates
NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-
induced microgliosis. Brain 137, 78–91
36. Boutten, A. et al. (2011) NRF2 targeting: a promising therapeutic
strategy in chronic obstructive pulmonary disease. Trends Mol.
Med. 17, 363–371
37. Dosch, S.F. et al. (2009) SARS coronavirus spike protein-induced
innate immune response occurs via activation of the NF-kappaB
pathway in human monocyte macrophages in vitro. Virus Res.
142, 19–27
38. Zhu, N. et al. (2020) A novel coronavirus from patients with pneu-
monia in China, 2019. N. Engl. J. Med. 382, 727–733
39. Chen, Y. et al. (2020) Structure analysis of the receptor
binding of 2019-nCoV. Biochem. Biophys. Res. Commun.
525, 135–140
40. Lopes, R.D. et al. (2020) Continuing versus suspending
angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers: impact on adverse outcomes in hospitalized
patients with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) – the BRACE CORONA trial. Am. Heart J.
226, 49–59
41. Mehta, P.K. and Griendling, K.K. (2007) Angiotensin II cell
signaling: physiological and pathological effects in the cardiovas-
cular system. Am. J. Physiol. Cell Physiol. 292, C82–C97
42. Magrone, T. et al. (2020) Focus on receptors for coronaviruses
with special reference to angiotensin-converting enzyme 2 as a
potential drug target – a perspective. Endocr. Metab. Immune
Disord. Drug Targets. Published online April 27, 2020. https://
doi.org/10.2174/1871530320666200427112902
43. Zhao, S. et al. (2018) Nrf2 deficiency upregulates intrarenal
angiotensin-converting enzyme-2 and angiotensin 1–7 receptor
expression and attenuates hypertension and nephropathy in dia-
betic mice. Endocrinology 159, 836–852
44. Nakagawa, K. et al. (2016) Viral and cellular mRNA translation in
coronavirus-infected cells. Adv. Virus Res. 96, 165–192
45. Krahling, V. et al. (2009) Severe acute respiratory syndrome coro-
navirus triggers apoptosis via protein kinase R but is resistant to its
antiviral activity. J. Virol. 83, 2298–2309608 Trends in Pharmacological Sciences, September 2020, Vol. 41, No. 9
Trends in Pharmacological Sciences46. Komatsu, M. et al. (2010) The selective autophagy substrate p62
activates the stress responsive transcription factor Nrf2 through in-
activation of Keap1. Nat. Cell Biol. 12, 213–223
47. Taguchi, K. et al. (2012) Keap1 degradation by autophagy for the
maintenance of redox homeostasis. Proc. Natl. Acad. Sci. U. S.
A. 109, 13561–13566
48. Chan, C.P. et al. (2006) Modulation of the unfolded protein
response by the severe acute respiratory syndrome coronavirus
spike protein. J. Virol. 80, 9279–9287
49. Cullinan, S.B. et al. (2003) Nrf2 is a direct PERK substrate and ef-
fector of PERK-dependent cell survival. Mol. Cell. Biol. 23,
7198–7209
50. Loo, Y.M. et al. (2008) Distinct RIG-I and MDA5 signaling by RNA
viruses in innate immunity. J. Virol. 82, 335–345
51. Burdette, D.L. et al. (2011) STING is a direct innate immune sensor
of cyclic di-GMP. Nature 478, 515–518
52. Sun, L. et al. (2012) Coronavirus papain-like proteases negatively
regulate antiviral innate immune response through disruption of
STING-mediated signaling. PLoS One 7, e30802
53. Chen, X. et al. (2014) SARS coronavirus papain-like protease
inhibits the type I interferon signaling pathway through interac-
tion with the STING–TRAF3–TBK1 complex. Protein Cell 5,
369–381
54. Acharya, D. et al. (2020) Dysregulation of type I interferon
responses in COVID-19. Nat. Rev. Immunol. 20, 397–398
55. Olagnier, D. et al. (2017) Activation of Nrf2 signaling augments ve-
sicular stomatitis virus oncolysis via autophagy-driven suppression
of antiviral immunity. Mol. Ther. 25, 1900–1916
56. Olagnier, D. et al. (2018) Nrf2 negatively regulates STING
indicating a link between antiviral sensing and metabolic
reprogramming. Nat. Commun. 9, 3506
57. Espinoza, J.A. et al. (2017) Modulation of antiviral immunity by
heme oxygenase-1. Am. J. Pathol. 187, 487–493
58. Koliaraki, V. and Kollias, G. (2011) A new role for myeloid HO-1 in
the innate to adaptive crosstalk and immune homeostasis. Adv.
Exp. Med. Biol. 780, 101–111
59. Bafna, K. et al. (2020) Structural similarity of SARS-CoV2 M(pro)
and HCV NS3/4A proteases suggests new approaches for iden-
tifying existing drugs useful as COVID-19 therapeutics. ChemRxiv
Published online April 21, 2020. http://dx.doi.org/10.26434/
chemrxiv.12153615
60. Baez-Santos, Y.M. et al. (2015) The SARS-coronavirus papain-
like protease: structure, function and inhibition by designed
antiviral compounds. Antivir. Res. 115, 21–38
61. Zhu, Z. et al. (2010) Biliverdin inhibits hepatitis C virus nonstructural
3/4A protease activity: mechanism for the antiviral effects of heme
oxygenase? Hepatology 52, 1897–1905
62. Fillebeen, C. et al. (2005) Iron inactivates the RNA polymerase
NS5B and suppresses subgenomic replication of hepatitis C Vi-
rus. J. Biol. Chem. 280, 9049–9057
63. Fillebeen, C. and Pantopoulos, K. (2010) Iron inhibits replication of
infectious hepatitis C virus in permissive Huh7.5.1 cells.
J. Hepatol. 53, 995–999
64. Gao, Y. et al. (2020) Structure of the RNA-dependent RNA
polymerase from COVID-19 virus. Science 368, 779–782
65. Tung, W.H. et al. (2011) Enterovirus 71 induces integrin
beta1/EGFR-Rac1-dependent oxidative stress in SK-N-SH cells:
role of HO-1/CO in viral replication. J. Cell. Physiol. 226,
3316–3329
66. Ma, Z. et al. (2017) Carbon monoxide and biliverdin suppress
bovine viral diarrhoea virus replication. J. Gen. Virol. 98,
2982–2992
67. Kalyanaraman, H. et al. (2018) Protein kinaseG activation reverses
oxidative stress and restores osteoblast function and bone forma-
tion in male mice with type 1 diabetes. Diabetes 67, 607–623
68. Cleary, S.J. et al. (2020) Animal models of mechanisms of SARS-
CoV-2 infection and COVID-19 pathology. Br. J. Pharmacol.
Published online May 27, 2020. https://doi.org/10.1111/
bph.15143
69. Lee, C. (2018) Therapeutic modulation of virus-induced oxidative
stress via the Nrf2-dependent antioxidative pathway. Oxidative
Med. Cell. Longev. 2018, 6208067
70. Komaravelli, N. and Casola, A. (2014) Respiratory viral
infections and subversion of cellular antioxidant defenses.
J. Pharmacogenomics Pharmacoproteomics 5, 1000141
71. Robledinos-Anton, N. et al. (2019) Activators and inhibitors
of NRF2: a review of their potential for clinical development.Oxida-
tive Med. Cell. Longev. 2019, 9372182
72. Linker, R.A. et al. (2011) Fumaric acid esters exert neuroprotective
effects in neuroinflammation via activation of the Nrf2 antioxidant
pathway. Brain 134, 678–692
73. Grzegorzewska, A.P. et al. (2017) Dimethyl fumarate ameliorates
pulmonary arterial hypertension and lung fibrosis by targeting mul-
tiple pathways. Sci. Rep. 7, 41605
74. Kobayashi, K. et al. (2015) Dimethyl fumarate suppresses
Theiler's murine encephalomyelitis virus-induced demyelinat-
ing disease by modifying the Nrf2-Keap1 pathway. Int.
Immunol. 27, 333–344
75. Mehta, D. et al. (2019) Effect of dimethyl fumarate on lymphocytes
in RRMS: Implications for clinical practice. Neurology 92,
e1724–e1738
76. Zhang, Y. et al. (1992) A major inducer of anticarcinogenic
protective enzymes from broccoli: isolation and elucidation of struc-
ture. Proc. Natl. Acad. Sci. U. S. A. 89, 2399–2403
77. Yagishita, Y. et al. (2019) Broccoli or sulforaphane: is it the source
or dose that matters? Molecules 24, 3593
78. Sun, Z. et al. (2018) Protective mechanism of sulforaphane in Nrf2
and anti-lung injury in ARDS rabbits. Exp. Ther. Med. 15,
4911–4915
79. Cho, H.Y. et al. (2019) Sulforaphane enriched transcriptome
of lung mitochondrial energy metabolism and provided
pulmonary injury protection via Nrf2 in mice. Toxicol. Appl.
Pharmacol. 364, 29–44
80. Cho, H.Y. et al. (2009) Antiviral activity of Nrf2 in a murine model of
respiratory syncytial virus disease. Am. J. Respir. Crit. Care Med.
179, 138–150
81. Fan, X. et al. (2013) Activating the Nrf2-mediated antioxidant re-
sponse element restores barrier function in the alveolar epithelium
of HIV-1 transgenic rats. Am. J. Physiol. Lung Cell. Mol. Physiol.
305, L267–L277
82. Kesic, M.J. et al. (2011) Nrf2 expression modifies influenza A entry
and replication in nasal epithelial cells. Free Radic. Biol. Med. 51,
444–453
83. Yu, J.S. et al. (2016) Sulforaphane suppresses hepatitis C virus
replication by up-regulating heme oxygenase-1 expression
through PI3K/Nrf2 pathway. PLoS One 11, e0152236
84. Greaney, A.J. et al. (2016) Sulforaphane inhibits multiple
inflammasomes through an Nrf2-independent mechanism.
J. Leukoc. Biol. 99, 189–199
85. Noah, T.L. et al. (2014) Effect of broccoli sprouts on nasal
response to live attenuated influenza virus in smokers: a
randomized, double-blind study. PLoS One 9, e98671
86. Shapiro, T.A. et al. (2006) Safety, tolerance, and metabolism of
broccoli sprout glucosinolates and isothiocyanates: a clinical
phase I study. Nutr. Cancer 55, 53–62
87. Sporn, M.B. et al. (2011) New synthetic triterpenoids: potent
agents for prevention and treatment of tissue injury caused
by inflammatory and oxidative stress. J. Nat. Prod. 74,
537–545
88. Dinkova-Kostova, A.T. et al. (2005) Extremely potent triterpenoid
inducers of the phase 2 response: correlations of protection
against oxidant and inflammatory stress. Proc. Natl. Acad. Sci.
U. S. A. 102, 4584–4589
89. Bharadwaj, S. et al. (2019) Discovery of Ganoderma lucidum
triterpenoids as potential inhibitors against Dengue virus NS2B-
NS3 protease. Sci. Rep. 9, 19059
90. Cinatl, J. et al. (2003) Glycyrrhizin, an active component of
liquorice roots, and replication of SARS-associated coronavirus.
Lancet 361, 2045–2046
91. Abo El-Magd, N.F. et al. (2018) Glycyrrhizin ameliorates high fat
diet-induced obesity in rats by activating NrF2 pathway. Life Sci.
193, 159–170
92. Rothan, H.A. et al. (2019) Small molecule grp94 inhibitors
block dengue and Zika virus replication. Antivir. Res. 171,
104590
93. Pei, X. et al. (2019) Bardoxolone treatment alleviates lipopoly-
saccharide (LPS)-induced acute lung injury through sup-
pressing inflammation and oxidative stress regulated by
Nrf2 signaling. Biochem. Biophys. Res. Commun. 516,
270–277Trends in Pharmacological Sciences, September 2020, Vol. 41, No. 9 609
Trends in Pharmacological Sciences94. Nio, Y. et al. (2019) Bardoxolone methyl as a novel potent antiviral
agent against hepatitis B and C viruses in human hepatocyte cell
culture systems. Antivir. Res. 169, 104537
95. Wang, Y.Y. et al. (2014) Bardoxolone methyl (CDDO-Me) as
a therapeutic agent: an update on its pharmacokinetic and phar-
macodynamic properties. Drug Des. Devel. Ther. 8, 2075–2088
96. Heiss, E. et al. (2001) Nuclear factor kappa B is a molecular target
for sulforaphane-mediated anti-inflammatory mechanisms. J. Biol.
Chem. 276, 32008–32015
98. Hahm, E.R. and Singh, S.V. (2010) Sulforaphane inhibits
constitutive and interleukin-6-induced activation of signal trans-
ducer and activator of transcription 3 in prostate cancer cells.
Cancer Prev. Res. (Phila.) 3, 484–494
99. Ahmad, R. et al. (2006) Triterpenoid CDDO-Me blocks the NF-
kappaB pathway by direct inhibition of IKKbeta on Cys-179.
J. Biol. Chem. 281, 35764–35769
100. Liby, K. et al. (2006) The synthetic triterpenoid CDDO-imidazolide
suppresses STAT phosphorylation and induces apoptosis in my-
eloma and lung cancer cells. Clin. Cancer Res. 12, 4288–4293
101. Mahase, E. (2020) Covid-19: demand for dexamethasone surges
as RECOVERY trial publishes preprint. BMJ 369, m2512
102. Russell, B. et al. (2020) COVID-19 and treatment with NSAIDs and
corticosteroids: should we be limiting their use in the clinical set-
ting? Ecancermedicalscience 14, 1023
103. Voiriot, G. et al. (2019) Risks related to the use of non-steroidal
anti-inflammatory drugs in community-acquired pneumonia in
adult and pediatric patients. J. Clin. Med. 8, 786
104. Clave, S. et al. (2019) The invisible threat of non-steroidal anti-
inflammatory drugs for kidneys. Front. Pediatr. 7, 520
105. Coxib et al. (2013) Vascular and upper gastrointestinal effects of non-
steroidal anti-inflammatory drugs: meta-analyses of individual partici-
pant data from randomised trials. Lancet 382, 769–779
106. Wen, Y.C. et al. (2018) Risk of stroke associated with use of non-
steroidal anti-inflammatory drugs during acute respiratory infection
episode. Pharmacoepidemiol. Drug Saf. 27, 645–651
107. Costela-Ruiz, V.J. et al. (2020) SARS-CoV-2 infection: the role of
cytokines in COVID-19 disease. Cytokine Growth Factor Rev.
Published online June 2, 2020. https://dx.doi.org/10.1016/j.
cytogfr.2020.06.001
108. Antwi-Amoabeng, D. et al. (2020) Clinical outcomes in COVID-
19 patients treated with tocilizumab: an individual patient data
systematic review. J. Med. Virol. Published online May 21,
2020. https://doi.org/10.1002/jmv.26038
109. González-García, A. et al. (2020) Successful treatment of severe
COVID-19 with subcutaneous anakinra as a sole treatment.
Rheumatology (Oxford). Published online June 22, 2020.
hppt://dx.doi.org/10.1093/rheumatology/keaa318
110. Schmidt, H.H. et al. (2015) Antioxidants in translational medicine.
Antioxid. Redox Signal. 23, 1130–1143
111. Gao, X. et al. (2001) Powerful and prolonged protection of hu-
man retinal pigment epithelial cells, keratinocytes, and mouse
leukemia cells against oxidative damage: the indirect antioxidant
effects of sulforaphane. Proc. Natl. Acad. Sci. U. S. A. 98,
15221–15226
112. Dinkova-Kostova, A.T. and Talalay, P. (2008) Direct and indirect
antioxidant properties of inducers of cytoprotective proteins.Mol.
Nutr. Food Res. 52, S128–S138
113. McGill, M.R. and Jaeschke, H. (2013) Metabolism and disposi-
tion of acetaminophen: recent advances in relation to hepatotox-
icity and diagnosis. Pharm. Res. 30, 2174–2187
114. Dinkova-Kostova, A.T. et al. (2007) Induction of the phase 2 re-
sponse in mouse and human skin by sulforaphane-containing
broccoli sprout extracts. Cancer Epidemiol. Biomark. Prev. 16,
847–851
115. Lazzara, P.R. et al. (2020) Isoquinoline Kelch-like ECH-
associated protein 1-nuclear factor (erythroid-derived 2)-like 2
(KEAP1-NRF2) inhibitors with high metabolic stability. J. Med.
Chem. 63, 6547–6560
116. Gorgulla, C. et al. (2020) An open-source drug discovery plat-
form enables ultra-large virtual screens. Nature 580,
663–668
117. Ni, G. et al. (2018) cGAS and STING: at the intersection
of DNA and RNA virus-sensing networks. PLoS Pathog. 14,
e1007148
118. Vivarini, A.C. et al. (2017) Systems approach reveals nu-
clear factor erythroid 2-related factor 2/protein kinase R
crosstalk in human cutaneous leishmaniasis. Front.
Immunol. 8, 1127610 Trends in Pharmacological Sciences, September 2020, Vol. 41, No. 9
